Freudenhammer M, Hufnagel M
Abteilung für Pädiatrische Infektiologie und Rheumatologie, Klinik für Allgemeine Kinder- und Jugendmedizin, Universitätsklinikum Freiburg, Mathildenstr. 1, 79106, Freiburg, Deutschland.
IMM-PACT Clinician Scientist Programm, Medizinische Fakultät, Universität Freiburg, Freiburg, Deutschland.
Z Rheumatol. 2021 Sep;80(7):620-628. doi: 10.1007/s00393-021-01002-6. Epub 2021 Apr 27.
Due to the underlying disease and immunosuppressive treatment, pediatric patients with rheumatic diseases are at increased risk for (long distance) travel-related health problems. A pretravel comprehensive consultation is therefore strongly recommended. Whether a child with rheumatic disease is sufficiently fit for travel essentially depends on the disease activity, the age of the child and the intended travel destination. Depending on the level of immunosuppression, the risks for this patient group include (travel-related) infections and the possibility of disease activity flares. Of particular importance is adequate exposure prevention: standard vaccinations should be updated and indications for travel vaccinations evaluated in advance of travelling. In this context, potential contraindications, especially for live vaccines, in the case of specific immunosuppressive treatment should be considered. In the event of travel to malaria endemic areas, the necessity for chemoprophylaxis or stand-by medication must be evaluated but caution is needed regarding potential drug interactions. Detailed education about careful hand, food and contact hygiene is critical. Because photosensitivity may be increased in some rheumatic diseases and/or medications, UV protection is crucial. Barriers (clothes and mosquito nets) and age-appropriate chemical insect repellents should be used to prevent insect-borne diseases. Before start of travel, possibilities for on-site medical help in the event of disease deterioration and/or infection should be evaluated. This should be included in the assessment of the patient's ability to travel. Travelers with rheumatic disease should carry a first aid kit that includes both a sufficient supply of regular antirheumatic medication and supplemental medication in case of a disease flare. Storage conditions must be taken ínto account for some medications. Ultimately, the success of a journey depends on the planning from the perspective of the child with its specific needs.
由于潜在疾病和免疫抑制治疗,患有风湿性疾病的儿科患者出现(长途)旅行相关健康问题的风险增加。因此,强烈建议进行旅行前综合咨询。患有风湿性疾病的儿童是否适合旅行,本质上取决于疾病活动度、儿童年龄和预定旅行目的地。根据免疫抑制水平,该患者群体面临的风险包括(旅行相关)感染以及疾病活动发作的可能性。特别重要的是要进行充分的暴露预防:应更新标准疫苗接种,并在旅行前评估旅行疫苗接种的适应症。在这种情况下,应考虑特定免疫抑制治疗情况下的潜在禁忌症,尤其是活疫苗的禁忌症。如果前往疟疾流行地区,必须评估化学预防或备用药物的必要性,但需要注意潜在的药物相互作用。关于手部、食物和接触卫生的详细教育至关重要。由于某些风湿性疾病和/或药物可能会增加光敏性,紫外线防护至关重要。应使用屏障(衣物和蚊帐)以及适合年龄的化学驱虫剂来预防虫媒疾病。在旅行开始前,应评估疾病恶化和/或感染时现场医疗救助的可能性。这应纳入对患者旅行能力的评估中。患有风湿性疾病的旅行者应携带一个急救包,其中包括足够的常规抗风湿药物供应以及疾病发作时的补充药物。对于某些药物,必须考虑储存条件。最终,旅行的成功与否取决于从有特殊需求的儿童角度进行的规划。